Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.
Press releases published on May 6, 2025
Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 6, 2025
WATERTOWN, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic …
Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome
GlobeNewswire
·
May 6, 2025
SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the first quarter ended March 31, 2025, and provided business highlights. “The completion of our BLA submission for …
Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update
GlobeNewswire
·
May 6, 2025
First quarter total revenue of $139 million, Crysvita® revenue of $103 million and Dojolvi® revenue of $17 million Reaffirm 2025 Financial Guidance: Total revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and …
Day One Reports First Quarter 2025 Financial Results and Corporate Progress
GlobeNewswire
·
May 6, 2025
OJEMDA™ (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 Achieved Q1 2025 OJEMDA™ (tovorafenib) net product revenue of $30.5 million Ended the first quarter with $473.0 million in cash, cash equivalents and short-term investments Company …
Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
GlobeNewswire
·
May 6, 2025
NEWTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the …
Cytokinetics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 6, 2025
PDUFA Date for Aficamten in Obstructive HCM Extended by FDA to December 26, 2025 Topline Results from MAPLE-HCM Expected in May Enrollment Completed in ACACIA-HCM; Topline Results Expected in 1H 2026 ~$1.1 Billion in Cash, Cash Equivalents and Investments …
Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 6, 2025
Q1 2025 net product revenue for ZORYVE® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible resets and insurance changes, and excluding the non-recurring …
SOUND Behavioral Health Launches “Orange Door” Campaign for Mental Health Awareness Month
GlobeNewswire
·
May 6, 2025
SEATTLE, May 06, 2025 (GLOBE NEWSWIRE) -- This May, in recognition of Mental Health Awareness Month, SOUND Behavioral Health is proud to launch the “Orange Door” campaign—a bold new initiative designed to raise awareness around the growing need for mental …
Late-Breaking Interim STENOVA Data Presented at Digestive Disease Week® 2025 Demonstrate Potential of AGMB-129 in Fibrostenosing Crohn’s Disease
GlobeNewswire
·
May 6, 2025
Antwerp, Belgium, May 6, 2025 – Agomab Therapeutics NV (“Agomab”) today announced late-breaking interim data from the ongoing STENOVA1 Phase 2a clinical trial for AGMB-129, an oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (TGF-β …
Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering
GlobeNewswire
·
May 6, 2025
HOUSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the closing of its previously announced …
Annual NMDP(SM) Gala in New York City Raises Over a Half Million Dollars, Enabling More Patients to Receive Life-Saving Cell Therapy
GlobeNewswire
·
May 6, 2025
MINNEAPOLIS, May 06, 2025 (GLOBE NEWSWIRE) -- NMDPSM hosted its annual gala in New York on Thursday, May 1, raising $525,000-- funds which will support patient financial assistance and innovative cell therapy research to improve post-transplant outcomes …
Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq
GlobeNewswire
·
May 6, 2025
CHICAGO, May 06, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R…
Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight
GlobeNewswire
·
May 6, 2025
New York, USA, May 06, 2025 (GLOBE NEWSWIRE) -- Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight Angioedema is a rapid swelling of the deeper …
Avadel Pharmaceuticals Announces Favorable Ruling in Appeal of Delaware Court Injunction
GlobeNewswire
·
May 6, 2025
- With this ruling, Avadel can seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia - - Federal Circuit decision permits new clinical trials and further development of LUMRYZ™ for the treatment of indications beyond narcolepsy - DUBLIN, …
Guided Spinal Navigation Landmark Surgery Opens the Door to Cost-Effective 3D Augmented Reality
GlobeNewswire
·
May 6, 2025
Salt Lake City, May 06, 2025 (GLOBE NEWSWIRE) -- A groundbreaking surgical procedure was successfully performed on a small island in the Mediterranean, marking a significant advancement in spinal surgery. At Hospital Son Llàtzer in Mallorca, Spain, Dr. …
Beacon Therapeutics Announces Positive Phase 2 Interim 6-Month Data from DAWN Trial of Laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at ARVO 2025
GlobeNewswire
·
May 6, 2025
Data showed improvements across several key measures of visual function, including low luminance visual acuity and microperimetry Laru-zova was generally well-tolerated by DAWN participants at 6 months LONDON and CAMBRIDGE, Mass., May 06, 2025 (GLOBE …
Pasithea Therapeutics Announces Pricing of $5 Million Public Offering
GlobeNewswire
·
May 6, 2025
MIAMI, May 06, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics, Corp. (“Pasithea,” or the “Company”) (Nasdaq: KTTA; KTTAW), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of …
BrandSpark and Newsweek Announce 2025 Best New Product Award Winner: Premom’s Premium Prenatal Multivitamin
GlobeNewswire
·
May 6, 2025
Darien, Illinois, May 06, 2025 (GLOBE NEWSWIRE) -- Fertility and pregnancy support pioneer, Premom, is proud to announce that its Premium Prenatal Multivitamin has been awarded the prestigious 2025 Best New Product Award as part of the 17th annual Best New …
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
GlobeNewswire
·
May 6, 2025
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 6 May 2025 at 18.00 EEST Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure …
Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoitus (BlackRock, Inc.)
GlobeNewswire
·
May 6, 2025
ORION OYJ PÖRSSITIEDOTE / SUURIMMAT OSAKKEENOMISTAJAT -TIEDOTE 6.5.2025 KLO 18.00 Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoitus (BlackRock, Inc.) Orion Oyj on saanut Arvopaperimarkkinalain 9. luvun 5 §:n …